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As cancer therapeutics continues to improve and progress, the adverse side effects 
associated with anticancer treatments have also attracted more attention and have 
become extensively explored. Consequently, the importance of posttreatment fol-
low-ups is becoming increasingly relevant to the discussion. Contemporary treatment 
methods, such as tyrosine kinase inhibitors, anthracycline chemotherapy, and immuno-
therapy regimens are effective in treating different modalities of cancers; however, these 
reagents act through interference with DNA replication or prevent DNA repair, causing 
endothelial dysfunction, generating reactive oxygen species, or eliciting non-specific 
immune responses. Therefore, cardiotoxic effects, such as hypertension, heart failure, 
and left ventricular dysfunction, arise posttreatment. Rising awareness of cardiovascular 
complications has led to meticulous attention for the evolution of treatment strategies 
and carefully monitoring between enhanced treatment effectiveness and minimization 
of adverse toxicity to the cardiovasculature, in which psychological assessments, early 
detection methods such as biomarkers, magnetic resonance imaging, and various drugs 
to reverse the damage from cardiotoxic events are more prevalent and their emphasis 
has increased tremendously. Fully understanding the mechanisms by which the risk 
factors action for various patients undergoing cancer treatment is also becoming more 
prevalent in preventing cardiotoxicity down the line.
Keywords: cardiotoxicity, anticancer therapies, signaling pathway inhibitors, chemotherapy, immunotherapy, 
cardiotoxicity early detection and prevention
inTRODUCTiOn
In the past few decades, anticancer treatment has achieved remarkable progress in improving the 
quality of life and survival rates of cancer patients. The exploration and application of novel cancer 
therapeutics have increased tremendously, paralleled with the growth and abundance of literature 
surrounding the mechanisms underlying cancer metastasis. Novel drug therapies focusing on 
targeting signaling pathways pertaining to angiogenesis to prevent cellular proliferation via kinase 
inhibitors have especially been promising. Other methods, including anthracycline chemotherapy, 
have dramatically improved the outcomes of cancer treatment over the last 10 years (1). However, 
accompanying with the significant improvements toward cancer treatment, cardiotoxicity-related 
adverse effects caused by these anticancer therapies, specifically on deleterious cardiovascular effects, 
such as hypertension, heart failure, QT interval prolongation, and left ventricular dysfunction (LVD) 
(2–5), as well as heart failure with preserved preserved left ventricular ejection fraction (HFpEF), are 
increasingly reported (6). The development of cardiotoxicity has also been associated with patient 
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age, existing health conditions (at risk of cardiac dysfunction), 
treatment dosage, and other risk factors (7). Thus, carefully 
monitoring the development, early detection and prevention 
of cardiotoxicity, as well as understanding of the interaction 
between cancer and the cardiovascular system, thereby promot-
ing the development of safer cancer therapeutics, without or with 
minimized cardiotoxicity, are urgently needed (5).
In this review, we discuss contemporary methods of cancer 
therapy and the related signaling pathways, which are promot-
ing heart dysfunction and are affected through inhibitory drug 
treatments that are often compounded with chemotherapy 
and radiotherapy. We also discuss the importance of the novel 
therapeutic detection approaches for cardiotoxicity, namely, early 
detection via biomarkers and cardiovascular imaging, including, 
but not limited to, magnetic resonance imaging. These alternative 
treatment routes may provide more insight into the efficacy of 
cancer treatment strategies and cancer diagnostic tools, which 
highlight the importance of early detection to avoid later onset of 
adverse cardiotoxic effects.
CARDiOTOXiCiTY BY AnTiCAnCeR 
TReATMenT
The National Cancer Institute defines cardiotoxicity as “toxicity 
that affects the heart.” Cardiotoxicity may be acute, which occurs 
during or soon after treatment and is transient, or chronic, and 
can be categorized into type I (early onset) and type II (late 
onset) (5). Type I is irreversible cardiac cell injury and usually 
caused by anthracyclines and chemotherapeutics; type II is 
typically caused by novel biological-targeted antibodies (8). 
Chemotherapy and metabolic pathway inhibition has been 
shown to create adverse side effects, predominantly focusing on 
myocardial damage and the risks associated with heart failure 
posttreatment, although the newly emerged targeted drugs such 
as tyrosine kinase inhibitors and antibodies induce toxicities 
different from chemotherapy. Often, cardiotoxicity is com-
monly associated with LVD and other symptoms of systemic 
heart failure. Furthermore, LVD condition has several facets, 
which can be related to myocardial toxicity but also to other 
cardiovascular toxicities, namely, QTc prolongation, arrhyth-
mia, myocardial ischemia induced through atherosclerosis, 
and pulmonary hypertension. Especially, HFpEF (also called 
diastolic heart failure) occurs when the lower left ventricle is 
unable to properly fill with blood during the diastolic phase, 
and increasingly arises in patients undergoing chemotherapy, 
and may become predominant HF. Because the pathophysiology 
underlying HFpEF is heterogeneous, has different phenotypes, 
and is poorly understood, the etiological definition of HFpEF is 
variable. Thus, accurate diagnosis is challenging, and currently 
there is no effective therapy for HFpEF (6, 9–11). However, 
recently identified novel biomarkers, such as protein biomarker 
of cardiac stress (ST2), matrix metalloproteinase-2, and growth 
differentiation factor-15, for the risk stratification of HFpEF may 
be used for development of significant therapeutic targets for the 
treatment of HFpEF (12). Furthermore, recent advancements in 
imaging techniques and exploration into biomarkers have raised 
the important issue of the multiple comorbidities of cardiotoxic-
ity, many of which are not agglomerated through drug therapies.
Currently, there is no consensus definition of cardiotoxicity. 
The Cardiac Review and Evaluation Committee of trastuzumab-
associated cardiotoxicity defines cardiotoxicity as symptoms of 
heart failure, decline of left ventricular ejection fraction (LVEF), 
symptomatic fall in LVEF ≥5 to <55% or an asymptomatic 
reduction of LVEF ≥10 to <55% (13). The American Society of 
Echocardiography and European Association of Cardiovascular 
Imaging define cardiotoxicity as global longitudinal strain (GLS) 
with a 10–15% early reduction (http://asecho.org/wordpress/wp-
content/uploads/2015/12/MLM-Revised-Strain-Code-11-12-15.
pdf). The Food and Drug Administration defines LVEF drop 
<40–45% or is 40–49% with a ≥10% absolute decrease below 
baseline with anti-HER2 targeted therapy as being necessary to 
be monitored (14).
The Common Terminology Criteria for Adverse Events 
(CTCAE) is a descriptive terminology that is used for adverse 
event reporting based on a grading scale ranging from 1 to 5, 
with 1 being abnormal elevations in biomarker expression or 
imaging abnormalities, to 5, death due to cardiotoxicity (CTCAE, 
version 4.0 National Cancer Institute, June 14, 2010). However, 
the current reporting scale may be confusing and depends highly 
on symptomology, which may not represent a clear image of LVD 
abnormalities, for example, with patients who are asymptomatic. 
Finally, attributing signs and symptoms of cardiotoxicity prove 
to be difficult, as many symptoms are may not be induced or 
attributable to the drug therapy itself. This is especially challeng-
ing in older patients, whom often have common comorbidities.
Although the current scale may be deficient in some ways, it 
is important to address the limitations of potential definitions. 
Research of this magnitude requires consistency in defining the 
issue to share a common language and reinforce validity in the 
research.
COnTeMPORARY THeRAPeUTiCS FOR 
neOPLASiA
Currently, immunotherapies use the immune system to enhance 
their antitumor immunity and further immune responses by 
employing immune checkpoint inhibitors, chimeric antigen 
receptor (CAR) T cell therapy, and adaptive cell transfer (ACT) 
(using the patient’s own T-cells, engineered to specifically target 
cancer cells) have been promising in certain cancer treatments 
(15). Other targeted therapies, specifically focusing on signal-
ing pathway inhibition to prevent certain cell processes from 
occurring, namely, angiogenesis, also improve clinical outcomes. 
Angiogenesis, a normal process in which blood vessels are created 
through currently existing vessels, is a vital process in wound heal-
ing, growth, and development. However, growing tumors hijack 
this process to feed and proliferate tumor cells, thereby creating 
malignant tumor vessels within the body, making angiogenesis a 
key factor for tumor growth and survival.
One of the most prominently used and evaluated strategies is 
the inhibition of the vascular endothelial growth factor (VEGF) 
signaling cascade. VEGF plays a critical role in angiogenesis 
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through binding VEGF receptors and activating the VEGF sign-
aling pathway. Inhibition of angiogenesis, thereby, prevents 
growing tumors from hijacking the body’s natural process (16). 
Another popular target for cancer therapies is the human epider-
mal growth factor receptor 2 (HER2). The HER2 protein, also 
called ERBB2, is commonly overexpressed in patients with breast 
cancer, which accounts for approximately 15–30% cases in breast 
cancer (17, 18). Normally, HER2 helps in growth, proliferation, 
and repairing of abnormal cells within the body. However, similar 
to the VEGF signaling pathway, tumorigenesis takes control of 
the cellular process and promotes the proliferation of cancer cells 
(19, 20).
Trastuzumab (Herceptin), a monoclonal antibody, specifically 
targets HER2. Treatment regimens with Trastuzumab, coupled 
with chemotherapy, have shown remarkable outcomes in patients 
with breast cancer after 1  year (21). Anthracycline antibodies, 
including doxorubicin (DOX), have also been a consistent and 
prominent form of chemotherapy schemes for nearly half a 
century. By limiting proliferation of cancer cells via preventative 
interference with its DNA or RNA structure, DOX is able to halt 
tumorigenesis and ultimately stop cancer cell proliferation and 
division (8, 22).
TARGeTinG THe veGF SiGnALinG 
PATHwAY
Vascular endothelial growth factor and its corresponding receptors, 
VEGFR, are one of the most important tyrosine kinase pathways. 
VEGF includes seven members in its family—VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E, VEGF-F, and PIGF. VEGF-A is the 
most representative component. VEGF-A mRNA is expressed in 
various tissues in the body, such as the lung, kidney, and heart 
(16). Consequently, the VEGF signaling pathway plays a central 
role in other signaling pathways which also affect the vasculature, 
and any alterations to this pathway have been shown to exhibit 
deleterious effects (23).
Mechanistically, VEGF binds to three receptor sites—VEGFR-1 
(Flt-1), VEGFR-2 (Flk-1), and VEGFR-3 (24). Binding of VEGF 
to VEGFR-2 initiates the tyrosine signaling cascade, which then 
facilitates cell migration, proliferation, growth, and vasodilation, 
all of which are important and contribute to the development of 
angiogenesis (25). Historically, the VEGF pathway can be targeted 
using several different methods, including the molecule itself 
(monoclonal antibodies), receptors (recombinants), or down-
stream signaling pathways and inhibiting downstream expression 
(tyrosine kinase inhibition) (4).
Current antiangiogenesis therapies, including the inhibition of 
VEGF, have shown to have adverse effects on the cardiovascular 
system (2, 7, 16). VEGFR-1 and VEGFR-2 are both expressed 
naturally in endothelial cells (EC) (26). Due to the nature of 
inhibitory drug therapies, affecting the expression and interac-
tion between VEGF and its receptor sites affects the entire 
circulatory system and primarily induces proliferation of EC and 
promoting vascular integrity. Anti-VEGF therapies, such as the 
tyrosine kinase inhibitor, imatinib, dasatinib, nilotinib, bosutinib, 
sunitinib, sorafenib, axitinib, and ponatinib, exacerbate LVD, 
as well as incidences of hypertension, ischemic events, rapid 
acceleration of atherosclerosis, and other vascular toxic events 
(27). Inhibition of the VEGF pathway, therefore, can lead to 
endothelial dysfunction, arising from the disruption of normal 
endothelial homeostasis mediated through nitric oxide (23).
Meta-analyses with sunitinib have shown increased relative 
risk for cardiovascular complications. In a meta-analysis of 9,387 
patients, the risk of myocardial ischemia caused by sunitinib was 
3.03-fold higher compared with placebo (28). Sunitinib has also 
been speculated to induce LVD risk in over 20% of patients (28). 
Ponatinib has been associated with significant cardiovascular 
toxicity, with an indication of 10% cardiovascular, 7% cerebro-
vascular, and 7% peripheral adverse events by 28 months after 
treatment. Hypertension was reported in 26% of patients treated 
with this drug (28).
TARGeTinG THe HeR2 SiGnALinG 
PATHwAY
Trastuzumab is a humanized monoclonal antibody that directly 
inhibits the HER2 signaling pathway. It is used as first-line 
therapy with chemotherapy and has been shown to be effective 
in 25–30% of breast cancer cases (5, 29). However, anti-HER2 
therapy was reported to increase the risk for asymptomatic 
decreased left ventricular ejection fraction, leading to complica-
tions such as systemic heart failure. Interestingly, the cardiotoxic 
effects are shown early (usually within weeks of initial treatment) 
and are independent of dosing regimens. The cardiotoxic effects 
are also type II, or reversible, and often not severe in terms of cell 
death or damage (3).
Mechanistically, Trastuzumab competes for binding sites on 
the extracellular domain of HER2 and inhibits the activation of 
the tyrosine kinase signaling pathway (30, 31). It has also been 
speculated that Trastuzumab also induces cell death via antibody 
treatment, although the data supporting the claim are not yet clear 
(32). Regardless, HER2 inhibition prevents cell repair and signifi-
cantly limits proliferation. However, it is speculated that because 
Trastuzumab’s effect is established through targeting the HER2 
signaling pathway, which regulates cell differentiation, survival, 
and repair in healthy tissues, the body’s myocytes cannot depend 
on the repair mechanism either, and that leads to cardiotoxicity 
when in the presence of anthracyclines (33). Supporting data also 
come from a study of 179 breast cancer patients, in which 44% of 
patients developed a cardiac event (e.g., he art failure or decreased 
ejection fraction) and a tenth developed a second event (34, 35).
AnTHRACYCLineS
Anthracyclines, a class of chemotherapy drugs, are traditional 
cancer therapies that have been effective in treating many forms 
of cancer for the last half century. One of the most prominently 
used and readily identifiable is the anthracycline DOX. DOX-
induced cardiotoxicity is classified as type I, or irreversible. 
It directly contrasts with Trastuzumab and HER2 inhibition 
by the fact that cardiotoxicity from DOX is dose dependent 
(usually doses ≥450 mg/m2) (36). Moreover, the risk for future 
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complications significantly increases with cumulative doses 
(37, 38). Although it was originally speculated that the risks for 
immediate, on-treatment events decreased with lower doses, it 
is becoming more apparent that late onset complications can be 
verified regardless of dose. Therefore, there is no dosage regimen 
of DOX that is completely safe. The immediate cardiotoxic effects 
can range from a few weeks to years after treatment, even after 
the treatment has been discontinued. Incidences and reporting 
of LVD complications range from 1 to 20%, although the rate 
may be much higher (39). Some studies estimate that over half of 
the patients exposed to anthracyclines will develop some forms 
of LVD within 6 years (40). This claim is further supported by 
recent studies reporting the incidence of cardiotoxicity in 17.9 
and 6.3% of patients for subclinical and overt cardiotoxicity, 
respectively, in 9 years (41). Other studies have also shown LVEF 
in 98% of patients in a cohort of 9% (n = 226) overall incidence 
for cardiotoxicity within 1 year after chemotherapy (42).
Chemically, DOX has both hydrophilic and hydrophobic 
regions, allowing it to bind to both plasma proteins and cell 
membranes. DOX also has both acidic and base functions, its 
characteristics of being reoxidized results in the production of 
reactive oxygen species (ROS) and gives DOX an antineoplastic 
and antibiotic capabilities (8, 43). DOX has several different 
channels in which it affects the overall homeostasis in the body. 
One of the most important is its interaction with topoisomerase 
II. Topoisomerases are isomerase enzymes that participate in 
the overwinding or underwinding of DNA, allowing DNA to 
replicate by binding to the double strand DNA and overcome 
the tangles caused by the double helix. Topoisomerase II has 
two nuclear localized isoforms: topoisomerase IIα and IIβ. 
DOX inhibits topoisomerase interaction with DNA by directly 
binding to both IIα and IIβ, forming a DNA cleavage complex 
that increases double strand breakage (8, 22). Although DOX 
prevents cancer cells from replicating, it also serves as the 
primary cytotoxic reagent to induce cell apoptosis. DOX affects 
calcium homeostasis as well. It directly interferes with calcium 
storage capacity of the mitochondria by activating the selective 
CsA-sensitive calcium channel, causing calcium overload (8, 44) 
and leads to mitochondrial dysfunction, as well as apoptosis. 
The decreased calcium levels from the mitochondria have been 
shown to be irreversible. DOX, therefore, is highly versatile in 
terms of its uses, as well as its impact on the vasculature, and the 
cardiovascular system as a whole.
CAnCeR iMMUnOTHeRAPY
Cancer immunotherapy is a newly emerging treatment method 
which bases itself on the deeper understanding of the mechanism 
of antitumor immune responses, discoveries of novel antican-
cer molecules (peptides and vaccines), and development of 
innovative technologies of gene transfer (45). Current popular 
cancer immunotherapy employing inhibitory effects to immune 
checkpoint receptors has proven to be very effective in several 
malignancies and has shown very promising clinical outcomes in 
various types of cancers in the past 10 years. This revolutionized 
strategy has brought anticancer treatment into a new era (8, 45). 
Anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and 
anti-programmed cell death protein-1 (PD-1) have especially 
been beneficial to ailments, such as melanoma (46). Normally, 
cancer cells can utilize these receptors to avoid destruction via 
T cells in the immune system by binding to CLTA-4 and reduc-
ing naïve T cell activation or by expressing the cell death protein 
ligand-1 (PD-L1), which then binds to PD-1 and mediates T cell 
downregulation and apoptosis. Inhibitors, such as ipilimumab 
(anti-CTLA-4 monoclonal antibody) and pembrolizumab and 
nivolumab (anti-PD-1 monoclonal antibodies), bind to and block 
the inhibitory effects of the receptor sites, thus enhancing the 
cytotoxic immune response to the cancer cells (45).
Adoptive T cell transfer (ACT) is another novel and a promising 
method for a wide spectrum of solid cancer treatment. ACT uses a 
patient’s T cells to specifically target tumor cells. Mechanistically, 
tumor infiltrating lymphocytes (TILs) are collected and geneti-
cally engineered into a patient’s microenvironment along with 
systemic interleukin-2 (IL-2) to stimulate their survival and 
expansion (45). Successful implementation of ACT as a treatment 
modality for patients with metastatic melanoma has established 
the basis for multiple modifications and improvements of this 
strategy for targeting many different cancers (47). It has been 
reported that in 50% of patients with metastatic melanoma 
exhibit objective tumor regression by ACT using autologous TILs 
(47). As an innate cytokine in the immune system with essential 
and wide spectrum of immunological functions, IL-2 has long 
been used for cancer treatment alone and has shown great tumor 
regression (48, 49). IL-2 directly regulates T cell differentiation 
into different T  cells in response to antigens to enhance the 
defense of the immune system (48, 49). A recent report of 
a clinical study with patients treated with lymphodepleting 
conditioning chemotherapy followed by infusion of autologous 
TILs and high-dose IL-2 showed regression of metastatic uveal 
melanoma in 7 out of 20 patients, which had been believed to be 
resistant to immunotherapy previously (50). Similarly, chimeric 
antigen receptor (CAR)-T therapy has had valuable benefits to 
certain deficiencies, such as B cell acute lymphoblastic leukemia 
(B-ALL). Mechanistically, CAR-T functions very similar to ACT, 
wherein native T-cells are engineered to express a chimeric anti-
gen receptor on the cell membrane. The receptor is coupled with 
an external binding domain to specifically recognize and bind to 
tumor antigens. CAR-T also has an internal activation domain 
that then activates the T-cell once CAR-T binds to its target. In 
patients with B-ALL, CAR-T therapy is effective in 70–90% of 
cases (51).
However, the therapeutic effects are also counterbalanced 
with similar cardiotoxic effects (52–54). This is especially the case 
with immunotherapies, since activated T cell responses may be 
non-specific to cancer cells, thereby targeting normal tissue as 
well, leading to frequent immune-related adverse events (IRAEs) 
such as colitis, endocrinopathies, hepatitis, and pneumonitis. 
Other events, such as cardiomyopathy, myocardial fibrosis, 
myocarditis, and acute heart failure, were also reported in single 
anti-CTLA-4 or anti-PD-1 treatment (54), and lethal myocarditis 
accompanying with myositis was seen in combinatorial treatment 
(55), although such cases are rare. Patients using the monoclonal 
antibody ipilimumab have an IRAE frequency rate of 64–80% 
(54, 56, 57). Patients treated with pembrolizumab have an IRAE 
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frequency rate of up to 79% (54, 58). Combination therapies 
using both ipilimumab and nivolumab have been shown to have 
tremendous therapeutic efficacy and response rates in patients 
with melanoma from 19% using ipilimumab alone to 58% with 
the combination (46, 52). However, the frequency rate of IRAEs 
also increased parallel to the combination therapy, reaching as 
high as 96% in patients using both ipilimumab and nivolumab 
(59). CAR-T therapy and ACT both have associated risks with 
cardiotoxicity. CAR-T therapy, specifically, has links with cytokine 
release syndrome (CRS), an inflammatory response that is cor-
related with the activation of CAR-T cells. Manifestations of CRS 
include arrhythmias, decreased LVEF, and QT prolongation (60).
PRevenTiOn OF CARDiOTOXiCiTY AnD 
FUTURe DiReCTiOnS
Reversing certain effects of cancer drug therapies may not always 
be possible. However, current research into managing and moni-
toring cardiotoxicity and the various side effects arising from both 
modern and traditional therapeutics have been very promising. 
Dexrazoxane, a most promising cardioprotective agent, has been 
shown to be effective in reducing both acute and chronic cardio-
toxicity induced by anthracycline therapy (8, 61). Dexrazoxane 
has been shown to interfere with iron-dependent redox reactions, 
thereby reducing ROS originating from DOX (62). Dexrazoxane 
also directly inhibits topoisomerase IIβ, thereby preventing 
anthracycline binding and DNA double strand breaks (63). 
However, the ability of Dexrazoxane in reducing anthracycline-
induced cardiotoxicity has been limited in its clinical use because 
of adverse side effects (5). A recent clinical study indicated that 
Dexrazoxane, in addition to DOX, resulted in higher rates of bone 
marrow suppression, more febrile neutropenia events and dose 
reductions (64). Seeking novel protection of cardiotoxicity drugs 
is thereby more essential and in urgent demand.
Treatments modalities employed either before, after, or 
before and after cancer therapeutics have proven effective 
when dealing with certain cardiotoxic effect risk factors, such 
as heart failure. The use of beta blockers (BBs), angiotensin-
converting enzyme (ACE) inhibitor, angiotensin inhibitors, 
and mineralocorticoid receptor antagonists have all shown 
promising results in preventing cardiac damage and is an active 
ongoing investigation area (7). BBs have antioxidant proper-
ties and were utilized for chemotherapy-induced LVEF and 
other systolic LV dysfunction. One of the new generation BBs 
and a most commonly used agent, carvedilol, showed strong 
antioxidant characteristics and greater protective effect on 
anthracycline-induced cardiomyopathy (6, 8). A recent report 
demonstrated that favorable effects of ACE inhibitors and BBs 
on preventing cardiotoxicity and improving survival of breast 
cancer patients treated with trastuzumab and/or anthracyclines 
(65). Moreover, beta-adrenergic blockade with nebivolol, 
metoprolol, lisinopril, etc., has also been proven to be effective 
for cardiomyopathy (66, 67). However, reports on some BBs 
demonstrating beneficial cardioprotective effects in patients 
with LVEF remains controversial (68). Novel modalities, such as 
lcz696 (valsartan/sacubitril) (69, 70) and ivabradine can also be 
used to treat heart failure and subsequent impaired myocardial 
systolic dysfunction (6, 71). Furthermore, the cardioprotective 
role of ranolazine (inhibition of late INa elevation) and phos-
phodiesterase-5 inhibitors has been reported (66). In addition, 
nutrition supplements and exercise have shown positive effects 
on cardiomyopathy (66). However, significant supportive clini-
cal data are still needed to prove the protective function of these 
novel agents in patients affected by cardiotoxic effects (7).
The role of biomarkers has also been important in early 
detection. Elevated or abnormal expression levels of several 
biomarkers can be used as indicators for screening and assess the 
risk factors for future cardiotoxicity complications. Interleukin-6 
(IL-6), a cytokine produced by adipose tissues, increases blood 
pressure and induces inflammation. Overexpression of IL-6 
inhibits cell apoptosis, stimulates angiogenesis, and plays a role 
in drug resistance (72). There have also been promising data 
exploring biomarkers that pertain to type I and type II cardiac 
events. Increases in troponin-I, brain-type natriuretic peptide 
(BNP), and N-terminal-pro-BNP have all been linked to drops 
in LVEF (5, 73). Plasma myeloperoxidase also predicts a decrease 
in cardiac function (7). MicroRNA has emerged as a potential 
marker for early onset of heart failure. miR-1, miR-133b, and 
miR-146a were all upregulated corresponding to DOX chemo-
therapy (74).
Early detection is vital when considering the deleterious effects 
that drug therapeutics may have. One facet in which early detec-
tion has been outlined is through the risk factors for both cardio-
vascular diseases and cancer. Shared risk factors, such as obesity, 
carcinogenic agent usage (e.g., tobacco, smoking, and alcohol), 
previous history of diabetes, hypertension, non-modifiable risk 
factors (e.g., age and sex), and physical activity, should all be 
taken into consideration, especially when pertaining to drug 
therapeutics, thereby minimalizing the risk of future cardiotoxicity 
events (75).
Current exploration into psychological stress as an additional 
risk factor is promising (76). The mechanism in which psycho-
logical distress plays in cardiovascular dysfunction is twofold, 
focusing on behavioral and pathophysiological. In terms of 
behavioral mechanisms, it is best understood that personality 
types, temperament, anxiety, and depression can influence and 
are related to other risk factors, such as unhealthy lifestyles, lack 
of exercise, smoking, and alcohol consumption (77). In terms 
of pathophysiological mechanisms, being under psychological 
distress may form complications such as platelet dysfunction, 
autonomic nervous system dysregulation, hypothalamic–pituitary– 
adrenal axis (HPA-axis) dysregulation, cellular aging, and 
inflammatory activation. Platelet activation has shown increases 
in patients with depression (78). The HPA-axis has a known 
role and association in cardiovascular dysfunction via cortisol 
regulation (79). Patients with depression, anxiety, and fatigue 
often show elevated cortisol levels (80). Patients with depression 
and anxiety also have shorter telomere length, a biomarker for 
cellular aging and also an associated risk factor for cardiovascular 
dysfunction (81).
Takotsubo cardiomyopathy (TC), known as stress cardiomyo-
pathy or broken heart syndrome, may be caused by emotional 
stress and long-term anxiety (82). TC shows similar images as 
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that of acute coronary syndrome and is characterized by dynamic 
electrocardiographic changes along with transient, severe, and 
reversible LVD, but unclear pathophysiological mechanisms 
(82, 83). It is more common in elder women and was taken 
into account only in recent years in cancer patients treated with 
anticancer drugs suggesting that chemotherapy can induce TC 
(83–85).
Detection and early screening of cardiotoxicity via imaging 
techniques have become more prevalent. Two-dimensional echo-
cardiography (2DE) has been the standard for quite some time. 
However, assessment of LVEF and GLS via three-dimensional 
echocardiography (3DE) and speckle-tracking echocardiog-
raphy, respectively, has been shown to be a valuable asset in 
early detection and is able to overcome many challenges that 
affect traditional 2DE methods (7, 86). Moreover, GLS seems 
to predate LVEF decreases, and impairment of GLS in HEpEF 
has been reported (87). Thus, GLS seems a better indicator of 
myocardial dysfunction prior heart failure progression. Cardiac 
magnetic resonance imaging has emerged in recent years and is 
used as the gold standard parameter. It is accurate, reproductive, 
and reliable and has higher sensitivity than 2DE and 3DE in 
detecting early changes in global and regional cardiac function, 
and its high contrast-to-noise ratio provides excellent structural 
characteristics (88, 89).
COnCLUSiOn
Cardiotoxicity is one of the most deleterious effects arising from 
cancer therapeutics and a major barrier to survivorship. However, 
today’s cancer patients should not be tomorrow’s cardiovascular 
disease patients. Recent research has shed the light of optimism 
with an emphasis on early prevention. Continued research and 
discussion will further advance our literature pertaining to 
cardiotoxicity, opening up additional avenues for safer treatment 
strategies. Further investigation into alternative therapeutics, as 
well as the increasing information and understanding of modern 
technologies in screening and detecting at-risk patients will be 
helpful in developing and evaluating different modalities for 
cancer therapeutics. Moreover, such research will be able to fill 
in the gaps in understanding cardiotoxicity and explore other 
avenues of research that are often overlooked.
Understanding the importance of risk factors and associated 
risks, such as the role of psychological distress, are necessary 
to advance the care of cancer patients. Minimizing the risk of 
cardiovascular complications induced through various therapies 
is vital to treatment and care. This, again, is an emphasis on the 
importance of early detection and risk assessment when consid-
ering drug administration to certain patients.
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